Biotechnology Assets SA
MAD:BST
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/IC
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Valuation Scenarios
If EV/IC returns to its 3-Year Average (1.4), the stock would be worth €0.26 (5% downside from current price).
| Scenario | EV/IC Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1.5 | €0.27 |
0%
|
| 3-Year Average | 1.4 | €0.26 |
-5%
|
| 5-Year Average | 1.3 | €0.23 |
-16%
|
| Industry Average | 0.8 | €0.15 |
-46%
|
| Country Average | 0.9 | €0.16 |
-42%
|
Forward EV/IC
Today’s price vs future invested capital
Peer Comparison
| Market Cap | EV/IC | P/E | ||||
|---|---|---|---|---|---|---|
| ES |
|
Biotechnology Assets SA
MAD:BST
|
18.5m EUR | 1.5 | -8.9 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -1 260 263.1 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
365.2B USD | 4.5 | 87.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
177.8B USD | 3.6 | 23 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
163.4B USD | 3.7 | 19.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 966.7 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.7B USD | 7.3 | 27.2 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
74.1B USD | 5.6 | 16.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.3B EUR | 14.8 | 37.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.8 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60.2B AUD | 1.5 | 29.5 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.7 |
| Median | 0.9 |
| 70th Percentile | 1.3 |
| Max | 31.5 |
Other Multiples
Biotechnology Assets SA
Glance View
Biotechnology Assets SA operates as a biopharmaceutical company. The company is headquartered in Jerez De La Frontera, Cadiz and currently employs 32 full-time employees. The company went IPO on 2011-06-14. The Firm’s main activities are: Research, development and production of biotechnological solutions aimed at improving the health and welfare of people and animals; Development, acquisition, transfer and exploitation of industrial and intellectual property rights; Distribution, marketing, export and import of the previously mentioned products. The Company, through its subsidiaries, is also present in Luxembourg, Hong Kong and USA.
